5 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow Standard: new trials by email Literature Review of Standard trials Research Report on Standard
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy, Standard systemic therapy (chemotherapy) without RT/SBRT - Radiation Therapy, SBRT | Phase 3 | Active not recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 108 | 2025-01-10 | 2025-04-27 |
| Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody Standard, Experimental - Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a | Phase 3 | Recruiting | Heidelberg University | 100 | 2022-07-06 | 2026-04-28 |
| The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia Imatinib Mesylate, Standard of Care - COVID-19 | Phase 3 | Unknown | Alexandria University | 30 | 2020-06-01 | 2020-06-09 |
| Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris Adapalene BPO Gel standard daily overnight application, Adapalene-BPO 3-hour daily application before bedtime, Adapalene-BPO Gel every other day application - Acne | Phase 3 | Completed | Galderma R&D | 123 | 2009-04-01 | 2021-02-18 |
| Surgical Site Infections After Liver Transplantation Based on Perioperative Antibiotics standard, extended, liver transplant - Liver Transplantation, Surgical Site Infection | Phase 3 | Completed | University of Virginia | 102 | 2009-03-01 | 2018-07-17 |
| Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Sirolimus, Standard - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 3 | Completed | University of Zurich | 100 | 2006-06-01 | 2014-02-27 |
| PROFIT - Prostate Fractionated Irradiation Trial 7800 cGy/39 fractions in 8 weeks, 6000 cGy/20 fractions in 4 weeks - Prostate Cancer | Phase 3 | Completed | Ontario Clinical Oncology Group (OCOG) | 1204 | 2006-05-01 | 2017-07-31 |
| Shorter Radiation Schedule for the Treatment of Prostate Cancer 5250 cGy/20 fractions over 28 days, 6600 cGy/33 fractions over 45 days - Prostate Cancer | Phase 3 | Completed | Ontario Clinical Oncology Group (OCOG) | 936 | 1995-03-01 | 2010-08-17 |
Prostatic Neoplasms (2) · Acne Vulgaris (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Pneumonia (1) · Polycystic Kidney, Autosomal Dominant (1) · Surgical Wound Infection (1)
Ontario Clinical Oncology Group (OCOG) (2) · Alexandria University (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Galderma R&D (1) · Heidelberg University (1) · University of Virginia (1) · University of Zurich (1)
Canada (3) · Australia (1) · France (1) · Germany (1) · Italy (1) · Switzerland (1)
Himu Lukka, MD (2) · Mark Levine, MD (2) · Andreas L. Serra, MD (1) · Charles Catton, MD (1) · Charles Hayter, MD (1) · Jerry Tan, MD (1) · Jim Julian, MMATH (1) · Klaus Herfarth, MD (1) · Robert G Sawyer, MD (1)
PMID 16135479, PMID 16221708, PMID 17868472, PMID 19525519, PMID 20581391, PMID 22417271, PMID 23071528, PMID 31723798, PMID 32799356, PMID 33539729, PMID 39356039, PMID 39914555, PMID 40335398
T32AI078875 (1)